If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful starting point is understanding what the current market price might be ...

Recursion Pharmaceuticals granted inducement RSU awards to 17 new employees under its 2024 Inducement Equity Incentive Plan. The awards are tied to recent hiring activity and are intended as ...

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...

We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

The last time I wrote about Recursion Pharmaceuticals, Inc. (RXRX), it was in a Seeking Alpha article entitled “Recursion: Path Forward For REC-994 Remains Despite Mixed Response.” In the article, I ...

The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...